Vemurafenib

Summary

Vemurafenib (CHEMBL1229517) is an approved small-molecule antineoplastic agent (ATC L01EC01) targeting BRAF and RAF1; indicated across 22 conditions including melanoma and metastatic melanoma; with CIViC clinical evidence for 186 variant-indication associations (e.g. BRAF V600 in melanoma).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01EC01
• Targets: 2 (BRAF, RAF1)
• Indications: 22 conditions
• Clinical trials: 132
• Precision-oncology evidence (CIViC): 186 variant–indication associations
• Chemistry: 489.9 Da · C23H18ClF2N3O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1229517
Name	Vemurafenib
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	42611257
ChEBI	CHEBI:63637
ATC	L01EC01
Molecular formula	C23H18ClF2N3O3S
Molecular weight	489.9
InChIKey	GPXBXXGIAQBQNI-UHFFFAOYSA-N

SMILES: CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F

IUPAC name: N-[3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]propane-1-sulfonamide

ChEBI definition: A pyrrolopyridine that is 1H-pyrrolo[2,3-b]pyridine which is substituted at position 5 by a p-chlorophenyl group and at positions 3 by a 3-amino-2,6-difluorobenzoyl group, the amino group of which has undergone formal condensation with propane-1-sulfonic acid to give the corresponding sulfonamide. An inhibitor of BRAF and other kinases.

Pharmacological roles (ChEBI): antineoplastic agent, B-Raf inhibitor.

Also known as: PLX-4032, PLX4032, RG 7204, RG-7204, RO 5185426, RO-5185426, Vemurafenib, Zelboraf, VEMURAFENIB, SID137275900, Vermurafenib, vemurafenib

Patent coverage: 6,490 distinct patent families (15,704 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 15,314 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
BRAF	B-Raf proto-oncogene, serine/threonine kinase	Inhibition	8.54	8.6%	P15056
RAF1	Raf-1 proto-oncogene, serine/threonine kinase	Inhibition	7.32		P04049

Broader ChEMBL bioactivity targets: 29 (assay-derived). Sample: Serine/threonine-protein kinase A-Raf, Receptor-interacting serine/threonine-protein kinase 3, RAF proto-oncogene serine/threonine-protein kinase, Epidermal growth factor receptor, Proto-oncogene tyrosine-protein kinase receptor Ret, Progesterone receptor, Muscarinic acetylcholine receptor M2, Dual specificity mitogen-activated protein kinase kinase; MEK1/2, Muscarinic acetylcholine receptor M1, GTPase KRas.

Bioactivity

ChEMBL activities: 109 potent at pChembl ≥ 5 of 119 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ARAF	8.68	IC50	2.1	nM	CHEMBL_ACT_18231155
ARAF	8.68	IC50	2.1	nM	CHEMBL_ACT_18951182
BRAF	8.49	IC50	3.2	nM	CHEMBL_ACT_13317268
BRAF	8.4	IC50	4	nM	CHEMBL_ACT_16577211
MAP3K20	8.4	IC50	4	nM	CHEMBL_ACT_25480615
RET	8.32	IC50	4.8	nM	CHEMBL_ACT_26023242
BRAF	8.21	IC50	6.1	nM	CHEMBL_ACT_15605041
BRAF	8.16	IC50	6.9	nM	CHEMBL_ACT_18231167
BRAF	8.16	IC50	6.9	nM	CHEMBL_ACT_18951188
P47809	8.09	Kd	8.2	nM	CHEMBL_ACT_23172103
BRAF	8.02	IC50	9.6	nM	CHEMBL_ACT_19094008
BRAF	8	Kd	10	nM	CHEMBL_ACT_25653262
BRAF	7.89	IC50	13	nM	CHEMBL_ACT_24998822
BRAF	7.89	IC50	13	nM	CHEMBL_ACT_25500426
BRAF	7.77	IC50	17	nM	CHEMBL_ACT_16578213
TNK2	7.72	IC50	19	nM	CHEMBL_ACT_25112618
TNK2	7.72	IC50	19	nM	CHEMBL_ACT_25532660
BRAF	7.7	IC50	20	nM	CHEMBL_ACT_16577173
BRAF	7.68	IC50	21	nM	CHEMBL_ACT_13317267
BRAF	7.68	IC50	21	nM	CHEMBL_ACT_18653819
BRAF	7.68	IC50	21	nM	CHEMBL_ACT_19098102
BRAF	7.64	IC50	23	nM	CHEMBL_ACT_14975801
MAP3K20	7.64	IC50	23	nM	CHEMBL_ACT_18255325
BRAF	7.58	IC50	26	nM	CHEMBL_ACT_14571422
P28028	7.52	IC50	30	nM	CHEMBL_ACT_18788650
BRAF	7.51	IC50	31	nM	CHEMBL_ACT_12114911
BRAF	7.51	IC50	31	nM	CHEMBL_ACT_16597917
BRAF	7.51	IC50	31	nM	CHEMBL_ACT_18528068
BRAF	7.51	IC50	31	nM	CHEMBL_ACT_18745562
BRAF	7.51	IC50	30.9	nM	CHEMBL_ACT_18745809

Target pathways

Aggregated over 2 target gene(s): BRAF, RAF1.

Top Reactome pathways

44 total, by targets touching each:

Pathway	Targets	Genes
RAF activation	2	BRAF, RAF1
MAP2K and MAPK activation	2	BRAF, RAF1
Negative feedback regulation of MAPK pathway	2	BRAF, RAF1
Negative regulation of MAPK pathway	2	BRAF, RAF1
Signaling by moderate kinase activity BRAF mutants	2	BRAF, RAF1
Signaling by high-kinase activity BRAF mutants	2	BRAF, RAF1
Signaling by BRAF and RAF1 fusions	2	BRAF, RAF1
Paradoxical activation of RAF signaling by kinase inactive BRAF	2	BRAF, RAF1
Signaling downstream of RAS mutants	2	BRAF, RAF1
Signaling by RAF1 mutants	2	BRAF, RAF1
SHOC2 M1731 mutant abolishes MRAS complex function	2	BRAF, RAF1
Gain-of-function MRAS complexes activate RAF signaling	2	BRAF, RAF1
Spry regulation of FGF signaling	1	BRAF
Signal Transduction	1	BRAF
Disease	1	BRAF
Signaling by NTRKs	1	BRAF
Prolonged ERK activation events	1	BRAF
Frs2-mediated activation	1	BRAF
ARMS-mediated activation	1	BRAF
Signaling by NTRK1 (TRKA)	1	BRAF
Signalling to ERKs	1	BRAF
Signalling to p38 via RIT and RIN	1	BRAF
Signaling by FGFR	1	BRAF
Stimuli-sensing channels	1	RAF1
Rap1 signalling	1	RAF1
GP1b-IX-V activation signalling	1	RAF1
CD209 (DC-SIGN) signaling	1	RAF1
Negative regulation of FGFR1 signaling	1	BRAF
Negative regulation of FGFR2 signaling	1	BRAF
Negative regulation of FGFR3 signaling	1	BRAF

Dominant GO biological processes

GO term	Targets
MAPK cascade	2
protein phosphorylation	2
thyroid gland development	2
positive regulation of peptidyl-serine phosphorylation	2
somatic stem cell population maintenance	2
negative regulation of apoptotic process	2
thymus development	2
face development	2
signal transduction	2
cell differentiation	2
myeloid progenitor cell differentiation	1
epidermal growth factor receptor signaling pathway	1
visual learning	1
animal organ morphogenesis	1
positive regulation of gene expression	1

Indications & clinical

Indications

22 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
melanoma	4	MONDO:0005105	EFO:0000756
metastatic melanoma	4	MONDO:0005191	EFO:0002617
neoplasm	4	MONDO:0005070	EFO:0000616
cutaneous melanoma	4	MONDO:0005012	EFO:0000389
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
craniopharyngioma	2	MONDO:0018907	EFO:1000209
hairy cell leukemia	2	MONDO:0018935	EFO:1000956
colorectal carcinoma	2	MONDO:0024331	EFO:1001951
colorectal adenocarcinoma	2	MONDO:0005008	EFO:0000365
Langerhans cell histiocytosis	2	MONDO:0018310	EFO:1000318
thyroid gland carcinoma	2	MONDO:0015075	EFO:0002892
histiocytosis	2	MONDO:0002637	HP:0100727
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
lymphoid neoplasm	2	MONDO:0005157	EFO:0001642
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
lymphoma	1	MONDO:0005062	EFO:0000574
skin neoplasm	1	MONDO:0002531	MONDO:0002898
paraganglioma	0	MONDO:0000448	EFO:1000453

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 132.

Phase distribution

Phase	Trials
PHASE2	60
PHASE1	41
PHASE3	9
PHASE1/PHASE2	8
Not specified	6
PHASE4	3
EARLY_PHASE1	3
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01683188	PHASE4	TERMINATED	HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
NCT01739764	PHASE4	COMPLETED	An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
NCT01898585	PHASE4	COMPLETED	An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
NCT03178552	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03768063	PHASE3	ACTIVE_NOT_RECRUITING	A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT05768178	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
NCT01006980	PHASE3	COMPLETED	A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
NCT01307397	PHASE3	COMPLETED	A Study of Vemurafenib in Participants With Metastatic Melanoma
NCT01597908	PHASE3	COMPLETED	Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
NCT01667419	PHASE3	COMPLETED	A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma
NCT01689519	PHASE3	COMPLETED	A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
NCT01909453	PHASE3	COMPLETED	Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
NCT02427893	PHASE3	WITHDRAWN	Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
NCT02908672	PHASE3	COMPLETED	A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
NCT01638676	PHASE1/PHASE2	RECRUITING	A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
NCT02304809	PHASE2	ACTIVE_NOT_RECRUITING	Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
NCT02693535	PHASE2	RECRUITING	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02925234	PHASE2	RECRUITING	The Drug Rediscovery Protocol (DRUP Trial)
NCT03155620	PHASE2	ACTIVE_NOT_RECRUITING	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03181100	PHASE2	ACTIVE_NOT_RECRUITING	Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
NCT03224767	PHASE2	ACTIVE_NOT_RECRUITING	Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
NCT03410875	PHASE2	ACTIVE_NOT_RECRUITING	A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
NCT04302025	PHASE2	RECRUITING	A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
NCT04423185	PHASE2	RECRUITING	PLATFORM Study of Precision Medicine for Rare Tumors
NCT04943198	PHASE2	RECRUITING	Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
NCT05159245	PHASE2	RECRUITING	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
NCT06440850	PHASE2	RECRUITING	Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
NCT06561360	PHASE2	RECRUITING	A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
NCT06603376	PHASE2	RECRUITING	Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer
NCT06692491	PHASE2	NOT_YET_RECRUITING	Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
NCT00949702	PHASE2	COMPLETED	A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
NCT01286753	PHASE2	COMPLETED	A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
NCT01378975	PHASE2	COMPLETED	A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
NCT01474551	PHASE2	TERMINATED	Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
NCT01495988	PHASE2	TERMINATED	Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
NCT01524978	PHASE2	COMPLETED	A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
NCT01586195	PHASE2	TERMINATED	Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
NCT01616199	PHASE1/PHASE2	TERMINATED	Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
NCT01659151	PHASE2	COMPLETED	Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
NCT01673854	PHASE2	COMPLETED	Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Clinical evidence (CIViC)

Variant × indication × effect (186 predictive associations from 251 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
BRAF V600	Melanoma	Sensitivity/Response	Cobimetinib + Vemurafenib	CIViC A	EID6044 +1
BRAF V600E	Skin Melanoma	Sensitivity/Response	Vemurafenib	CIViC A	EID1409 +1
BRAF V600	Erdheim-Chester Disease	Sensitivity/Response	Vemurafenib	CIViC A	EID11237
BRAF V600	Melanoma	Sensitivity/Response	Atezolizumab + Vemurafenib + Cobimetinib	CIViC A	EID11238
BRAF V600E	Melanoma	Sensitivity/Response	Vemurafenib	CIViC B	EID1398 +14
BRAF V600K	Melanoma	Sensitivity/Response	Vemurafenib	CIViC B	EID1399 +9
BRAF V600E	Hairy Cell Leukemia	Sensitivity/Response	Vemurafenib	CIViC B	EID11315 +6
BRAF V600E	Colorectal Cancer	Sensitivity/Response	Vemurafenib	CIViC B	EID1405 +4
BRAF V600E	Papillary Thyroid Carcinoma	Sensitivity/Response	Vemurafenib	CIViC B	EID1591 +4
BRAF V600E	Lung Adenocarcinoma	Sensitivity/Response	Vemurafenib	CIViC B	EID3782 +3
BRAF V600	Langerhans-cell Histiocytosis	Sensitivity/Response	Vemurafenib	CIViC B	EID11302 +1
BRAF V600E	Colorectal Cancer	Sensitivity/Response	Panitumumab + Vemurafenib	CIViC B	EID1413 +1
BRAF V600E	Colorectal Cancer	Sensitivity/Response	Vemurafenib + Irinotecan + Cetuximab	CIViC B	EID1902 +1
BRAF V600E	Anaplastic Thyroid Carcinoma	Sensitivity/Response	Vemurafenib	CIViC B	EID6045 +1
BRAF V600E	Lung Non-small Cell Carcinoma	Sensitivity/Response	Vemurafenib	CIViC B	EID5958 +1
BRAF K601E	Cancer	Sensitivity/Response	Vemurafenib	CIViC B	EID5963
BRAF V600	Melanoma	Sensitivity/Response	Vemurafenib + Cobimetinib	CIViC B	EID1422
BRAF V600	Lung Non-small Cell Carcinoma	Sensitivity/Response	Vemurafenib	CIViC B	EID1574
BRAF V600	Colorectal Cancer	Sensitivity/Response	Vemurafenib + Cetuximab	CIViC B	EID1598
BRAF V600	Cholangiocarcinoma	Sensitivity/Response	Vemurafenib	CIViC B	EID5905
BRAF V600	Colorectal Cancer	Sensitivity/Response	Cetuximab + Vemurafenib + Irinotecan	CIViC B	EID7355
BRAF V600E	Colorectal Cancer	Sensitivity/Response	Erlotinib + Vemurafenib	CIViC B	EID11427
BRAF V600E	Low Grade Glioma	Sensitivity/Response	Vemurafenib	CIViC B	EID11770
BRAF V600E	Melanoma	Sensitivity/Response	Cobimetinib + Vemurafenib	CIViC B	EID1421
BRAF V600E	Ovarian Cancer	Sensitivity/Response	Vemurafenib	CIViC B	EID5959
BRAF V600E	Langerhans Cell Sarcoma	Sensitivity/Response	Vemurafenib	CIViC B	EID7583
BRAF V600E OR BRAF K601E	Colorectal Cancer	Sensitivity/Response	Cobimetinib + Vemurafenib	CIViC B	EID11670
BRAF L505H	Melanoma	Resistance	Vemurafenib	CIViC B	EID1669 +1
MET Overexpression	Skin Melanoma	Resistance	Vemurafenib	CIViC B	EID1581 +1
RAC1 P29S	Melanoma	Resistance	Vemurafenib + Dabrafenib	CIViC B	EID7669 +1

+156 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

51 molecules share ≥1 primary target. Top 51 by shared-target count:

Molecule	Source	Status	Shared targets
GEFITINIB	ChEMBL + PubChem	Phase 4 (approved)	BRAF, RAF1
PAZOPANIB	ChEMBL + PubChem	Phase 4 (approved)	BRAF, RAF1
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	BRAF, RAF1
DABRAFENIB	ChEMBL	Phase 4 (approved)	BRAF, RAF1
DASATINIB	ChEMBL	Phase 4 (approved)	BRAF, RAF1
ERLOTINIB	ChEMBL	Phase 4 (approved)	BRAF, RAF1
IMATINIB	ChEMBL	Phase 4 (approved)	BRAF, RAF1
NILOTINIB	ChEMBL	Phase 4 (approved)	BRAF, RAF1
SORAFENIB	ChEMBL	Phase 4 (approved)	BRAF, RAF1
TOVORAFENIB	ChEMBL	Phase 4 (approved)	BRAF, RAF1
AVUTOMETINIB	ChEMBL	Phase 3	BRAF, RAF1
MOTESANIB	ChEMBL	Phase 3	BRAF, RAF1
NAPORAFENIB	ChEMBL	Phase 3	BRAF, RAF1
BELVARAFENIB	ChEMBL	Phase 2	BRAF, RAF1
BRIMARAFENIB	ChEMBL	Phase 2	BRAF, RAF1
CEP-32496	ChEMBL	Phase 2	BRAF, RAF1
DORAMAPIMOD	ChEMBL	Phase 2	BRAF, RAF1
EXARAFENIB	ChEMBL	Phase 2	BRAF, RAF1
FORETINIB	ChEMBL	Phase 2	BRAF, RAF1
R-406	ChEMBL	Phase 2	BRAF, RAF1
RAF-265	ChEMBL	Phase 2	BRAF, RAF1
REBASTINIB	ChEMBL	Phase 2	BRAF, RAF1
Afatinib	PubChem	Approved	BRAF, RAF1
Crizotinib	PubChem	Approved	BRAF, RAF1
Idelalisib	PubChem	Approved	BRAF, RAF1
Selumetinib	PubChem	Approved	BRAF, RAF1
ABEMACICLIB	ChEMBL	Phase 4 (approved)	BRAF
COBIMETINIB	ChEMBL	Phase 4 (approved)	BRAF
ENCORAFENIB	ChEMBL	Phase 4 (approved)	BRAF
FEDRATINIB	ChEMBL	Phase 4 (approved)	BRAF
INFIGRATINIB	ChEMBL	Phase 4 (approved)	BRAF
PONATINIB	ChEMBL	Phase 4 (approved)	BRAF
RUXOLITINIB	ChEMBL	Phase 4 (approved)	BRAF
MASITINIB	ChEMBL	Phase 3	BRAF
PLINABULIN	ChEMBL	Phase 3	RAF1
QUERCETIN	ChEMBL	Phase 3	BRAF
BAFETINIB	ChEMBL	Phase 2	BRAF
CI-1040	ChEMBL	Phase 2	RAF1
ELLAGIC ACID	ChEMBL	Phase 2	BRAF
LIFIRAFENIB	ChEMBL	Phase 2	BRAF
MIRDAMETINIB	ChEMBL	Phase 2	BRAF
PEXMETINIB	ChEMBL	Phase 2	BRAF
RISOVALISIB	ChEMBL	Phase 2	RAF1
TG100-115	ChEMBL	Phase 2	BRAF
TINLORAFENIB	ChEMBL	Phase 2	BRAF
TOLONIUM CHLORIDE	ChEMBL	Phase 2	RAF1
XL-281	ChEMBL	Phase 2	BRAF
Binimetinib	PubChem	Approved	BRAF
dacomitinib	PubChem	Approved	BRAF
Fostamatinib	PubChem	Approved	BRAF
Trametinib	PubChem	Approved	BRAF